Whilst many cases lack an identifiable cause, FGR is strongly associated with fetal demise, and accompanies 50% of unexplained stillbirths. (2) Positive correlations between low birthweight, increased risk of adult cardiovascular disease and stroke have been documented, with growing evidence of the latent consequences of adverse prenatal programming. (3, 4) In healthy pregnancy, umbilical resistance, measured antenatally by umbilical artery Doppler velocimetry, correlates accurately with postpartum fetal-side ex vivo placental perfusion resistance.(5) The placental villous microcirculation is an important locus of vascular resistance and reduced feto-placental blood flow threatens fetal growth and survival. (5, 6) Ordinarily, the upward adjustment of placental blood flow across gestation is critical in meeting growth demands, and for development. However, in FGR these feto-placental adaptations can fail, restricting the feto-placental circulation and compromising placental function. In its severest form, antenatal umbilical arterial Doppler velocimetry reveals atypical waveforms, such as absent or reversed end-diastolic flow. (7) (8) (9) Under conditions of altered placental blood flow, fetal hemoglobin (HbF) is thought to be upregulated in an attempt to compensate for chronic hypoxia. (10, 11) This excess may be transferred to the maternal circulation in pre-eclampsia, a disease associated with FGR, where placentally-derived cell free fetal hemoglobin (fHbF) has also been reported. (12) (13) (14) Whilst the direct impact of fHbF on the fetal circulation remains unclear, it is proposed that erythrocyte behaviour is disturbed in FGR, with elevations of nucleated red cells defined in the placenta in as many as 89% of cases, even those devoid of Doppler anomalies. (15, 16 ) Although difficult to substantiate in the fetus, perpetuated erythrocytes are known to rupture under modest elevations in vascular shear stress; conditions which, without doubt are present in FGR cases, and manifest by flow abnormalities on antenatal Doppler (17) . Under these circumstances, free hemoglobin release is inevitable, but under normal homeostasis remains finely regulated.
In the absence of innervation and autonomic regulation, the feto-placental unit is reliant upon humoral mechanisms for buffering feto-placental blood pressure. (18) Within this context, nitric oxide (NO) is critical for vasodilation and maintaining blood flow. (5, 18, 19) Whilst encapsulated in red cells, the NO scavenging capacity of hemoglobin is significantly reduced, by at least 1,000-fold. (20, 21) However, in its extracellular (free) form, sequestration of NO by oxyhemoglobin occurs instantaneously. In the feto-placental circulation, compromised induction of endogenous heme-oxygenase (HO-1), as a primary heme-scavenging enzyme, could exacerbate this situation. (22) Upregulation of HO-1 in the term placenta is expected from previous work demonstrating a protoporphyrin-induced increase in HO-1 expression, most notably in the stem villous vasculature. Attenuation of this pathway is already associated with increased TNFα-induced cytotoxicity. (23) We therefore hypothesise that cell free fetal hemoglobin is upregulated in the fetal circulation in growth restricted pregnancy, causing endothelial activation and vasoconstriction in the human feto-placental circulation in this disease.
Materials and Methods
Ethics: Tissues were acquired following informed written consent from women attending St Mary's Hospital, Manchester (all subjects), UK. Ethical approvals were obtained from the Licensing committee:
North West Research Ethics Committee (reference numbers: 08/H1010/55, 08/H1010/55 (+5), 11/NW/0650). All experiments were performed in accordance with relevant guidelines and regulations.
Research Volunteers: Placentas were obtained from normal singleton pregnancies. To define groups, an individualized birthweight centile (IBC) was calculated according to the GROW algorithm (Perinatal Institute, Birmingham, West Midlands, UK). Groups were normal or FGR. FGR diagnosis was based on the Delphi-consensus definition as solitary parameter of IBC below the 3rd centile for gestation. (24) Reagents: Unless otherwise stated, reagents were supplied by Sigma-Aldrich (Poole, Dorset, UK). fHbF was extracted from whole umbilical cord blood and purified as described previously. (25) Feto-placental vascular appearance in FGR: An archive of stored transmission electron micrographs (TEMs) of freshly fixed placental tissue from FGR (N=15) were analyzed for endothelial morphology and erythrocyte distribution. For this analysis, specimens of placenta had been obtained immediately after delivery and a small piece of villous tissue excised from beneath the centre of the basal plate. This was diced into small fragments with a razor blade on dental wax and fixed for 4 hours at room temperature in 2-5 % glutaraldehyde in 0.1 M cacodylate buffer pH 7.4. The tissue was then rinsed three times over 24 hours in buffer containing 3 mM calcium chloride. Post-fixation was carried out in 1% osmium tetroxide (TAAB Laboratories Equipment Ltd, Aldermaston, Berkshire, UK) in 0.05M sodium cacodylate buffer pH 7.4 for 1 hour at 4°C followed by a buffer rinsing step. The tissue was then dehydrated in an ascending alcohol series, treated twice with propylene oxide (TAAB Laboratories Equipment Ltd; 15 mins each) then left in a 1:1 mix of propylene oxide and TAAB epoxy resin for one hour at room temperature. It was then left overnight on a rotator at 4°C in a mixture of 1:3 propylene oxide and epoxy resin and the following day given three changes of fresh resin at 45°C for one hour each before being embedded in gelatin capsules and polymerised for 72 hours at 60°C. Semithin sections, 0.5µm thick, were cut on a ultramicrotome (LKB, Mount Holly, NJ, USA), stained with 1% toluidine blue in 1% borax, after which ultrathin sections were prepared with a glass knife, mounted on copper grids and stained with uranyl acetate and lead citrate. These were examined in an AEI EM6B electron microscope at an accelerating volage of 60kV and appropriate areas photographed. fHbF was measured using a sandwich-ELISA(26) (Lund University, Lund, Sweden) in venous cord plasma of normal and FGR pregnancies. Blood was taken at the cord insertion point and processed following the optimized method. Ninety six-well microtiter plates were coated with mouse anti-HbF antibodies (4µg/ml in PBS) overnight at ambient temperature. In the second step, wells were blocked for two hours using blocking buffer (1% BSA in PBS), followed by an incubation with HbF calibrator or the samples (normal n=12; FGR n=5 for 2 hours at ambient temperature). In the third step, HRP-conjugated mouse anti-HbF antibodies (diluted 1:5000) were added and incubated for 2 hours at ambient temperature. Finally, a ready-to-use 3,3′,5,5′-tetramethylbenzidine (Life Technologies, Stockholm, Sweden) substrate solution was added, reaction was stopped after 20 minutes using 1.0 M HCl and the absorbance was read at 450nm using a Wallac 1420 Multilabel Counter (Perkin Elmer Life Sciences, Waltham, MA, USA). Where sufficient plasma was available, plasma HO-1 expression was measured by immunoassay (Enzo Life Sciences, Exeter, Devon, UK). HO-1 was used as denominator for matched fHbF concentrations (fHbF:HO-1 ratio), subject to plasma availability (n=12). fHbF Assay Development: Human γ-chains were prepared by dissociation of purified HbF with pmercuribenzoate and acidic precipitation (27, 28) . The absolute purity of HbF (from contamination with HbA), and of γ-chains (from contamination with α-and β-chains), was determined by non-denaturing PAGE followed by blotting with purified anti-human γ-chain (26, 29) . Mouse antibodies to human γ-chains, specific for HbF, were produced and purified by AgriSera AB (Vännäs, Sweden). Anti-HbF antibodies were then conjugated with horseradish peroxidase (Lightning-Link HRP, Innova Biosciences, Cambridge, Cambridgeshire, UK) to provide a quantitative indirect reporter.
Measurement of

Additional biochemical validation of altered fHbF fetal plasma status in FGR:
In testing the hypothesis that fHbF is elevated in FGR, additional assays were performed on the same fetal plasma samples to validate expressional or hemolytic changes that might have occurred in vivo linked to changes in plasma fHbF status, including erythropoietin (EPO), hemopexin, haptoglobin and α-1 microglobulin (A1M). Measurement of lactate dehydrogenase (LDH) was also performed as a validation against artefactual hemolysis and undertaken according to manufacturer's instruction. All kits were from Abcam (Cambridge, Cambridgeshire, UK).
Effect of fHbF on feto-placental vascular resistance tested by ex vivo human dual placental perfusion:
Normal placentas (≥37 weeks) were perfused in open circuit using ex vivo dual circuit perfusion, as previously described in an adaptation of the model developed by Schneider et al. (30, 31) Briefly, fetal-side inflow hydrostatic pressure (FIHP) was monitored using a Medex pressure transducer (Digitimer, Welwyn Garden City, Hertfordshire, UK) and recorded using a Nanologger (Gaeltec Nanologger, Isle of Skye, Inner Hebrides, UK) following perfusion with Earle's Bicarbonate Buffer (EBB). Fetal-side flow rate was determined following assurance that NO-evoked, flow-mediated vasodilation was effective, by incrementally adjusting the flow rate and observing temporal flow mediated vasodilation. Minimum acceptable fetal-side venous return was ≥80% of arterial inflow. Maternal-side perfusion at 14mL/min was started when steady-state FIHP was reached and delivered evenly into the intervillous space by five cannulae.
fHbF was introduced from a syringe driver (Precidor model, Infors AG, Basel, Switzerland) into the fetal inflow-line through a pre-pump injection port, obtaining FIHP responses to a pathophysiological dose-range of fHbF found in fetal plasma (0.01-1.0mg/mL). Following completion, the fetal-circuit was equilibrated with 100µmol/L Nω-nitro-L-arginine (L-NNA), to inhibit endothelial nitric oxide synthase (eNOS) and the dose response to fHbF repeated. For each dose of fHbF and vehicle, FIHP within the ex vivo dual perfused placenta was compared to its previous steady-state, with alterations in resistance reported as an absolute change. As proof of concept, NO sequestration was corroborated in vitro using a published method, 0.3mg/mL fHbF was reacted with 120µmol/L diethyl-NONATE (DEA-NONOate), as further proof of NO catabolism with fHbF in the feto-placental circulation and a spectrophotometric survey conducted. Effects of fHbF on in-situ vascular morphology: Chorionic artery plate sections from placentas from normal pregnancy were exposed to 0.6mg/mL fHbF, and cultured at 37 o C for 48 hours. Control vessels were exposed to HBSS vehicle. Vessels were fixed in sodium cacodylate buffer (0.1M) pH 7.4 and the lumen exposed by longitudinal incision. Specimens were processed for scanning electron microscopy (SEM).
Effect
Effect of fHbF on HPAEC angiogenesis: HPAEC growth on Matrigel, a placental-derived basement membrane matrix (Corning, Bedford, Bedfordshire, UK) was utilised to assess angiogenesis. HPAECs (2.8 x 10 4 cells/mL) were observed after 24 hours' incubation with 0.3mg/mL fHbF or PBS as control. HPAECs assembled into capillary-like tubule networks on this matrix. Tubule formation was quantified by microscopy using systematic examination of seven fields per view. Image Pro 7 software (MediaCybernetics Inc, Silver Spring, MD, USA) was used to analyse the tubule formation in the presence of fHbF (0.3mg/mL) or PBS vehicle. These values were then multiplied together, which was used as a net measure of angiogenesis.
Proteomic endothelial 'cell stress' array and inflammatory pathway investigation: Flow-conditioned HPAEC cells were lysed (see above) and harvested into ice-cold RIPA buffer. Standardization was performed for equivalent protein loading (micro-BCA kit; Thermo Fisher). Cell stress array blotting was undertaken according to manufacturer's instructions (R&D Systems, Abingdon, Oxfordshire, UK). A proteomic profile was obtained from fHbF-exposed and unexposed cells.
For assessment of NFκB and cytokine release, HPAECs were exposed to fHbF (0.07-1.2mg/mL) in separate static culture and cells were fixed in methanol and immunofluorescence stained for NF-κB p65 and DAPI.
Cells were permibilised with 0.5% TritonX-100 (in PBS) for 30 minutes and washed with PBS before 0.01% sodium borohydride in TBS. This process was repeated three times before blocking with buffer (TBS/5% normal swine solution) and maintained for 1 hour at 21 o C. Cells were incubated overnight at 4 o C with NF-κB p65 1° antibody (Cell Signalling Technology, Leiden, The Netherlands) diluted 1:400 (TBS/1% BSA).
Anti-Rabbit IgG (Dako, Stockport, Cheshire, UK) at 1:50 dilution was used as a negative control. Cells were assessed using fluorescence microscopy (Ziess, Cambridge, Cambridgeshire, UK) and NF-kB translocation assessed using a qualitative method with DAPI overlay, and blinded to fHbF exposure dose on a three tier scale (definite, intermediary or negative activation).
HPAEC cells exposed to fHbF under static culture conditions were lysed using radioimmunoprecipitation assay buffer for ELISA studies using DuoSet® kits (R&D Ssystems, MN, USA). A panel of NFkB-related inflammatory cytokines and triggers to the canonical route of NFkB activation (IL1α, IL1β, TNFα) were measured. ELISAs were performed on cell lysates, and undertaken according to the manufacturer's instruction. Protein quantity was measured using a Bio-Rad DC Protein Assay (Bio-Rad, Watford, Hertfordshire, UK), allowing adjustment for protein content (34) . As a standardising method, results were analysed as a fold change from the control in each cell line.
Statistics: Data, tested for normality and analyzed using GraphPad Prism (La Jolla, CA, USA), are expressed as either mean +/-SE or median +/-range. Statistics are qualified throughout. P values <0.05
were considered significant.
Data availability:
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
Results
Patient demographics:
An extensive listing of separate pregnancy cohorts relating to each study group is given ( Table 1) . as an eNOS inhibitor, the starting baseline pressures were artificially elevated as expected, but peak elevations in FIHP were significantly attenuated, suggesting fHbF sequesters NO from the feto-placental circulation when it is present. As further corroboration in a separate experiment, we found the in vitro addition of DEA-NONOate, an NO donor, rapidly transformed oxyhemoglobin to methemoglobin (Supplementary Figure 2) , demonstrating sequestration by fHbF.
Feto-placental vascular characteristics in FGR:
fHbF reduces NO bioavailability in flow-conditioned endothelial cells: fHbF at FGR cord blood concentrations reduced total NO bioavailability (total NO x ) compared to vehicle, as determined by the Griess reaction ( Figure 3C ). fHbF disrupts endothelium laminar morphology: Exposure of placental chorionic plate arteries to 0.6mg/mL fHbF for 48 hours resulted in a dysmorphic luminal endothelial surface, with extensive cellblebbing not observed in control arteries ( Figures 4B & 4A, respectively) . Whilst a dysregulated morphology could only be found in some zones of the chorionic plate artery endothelium exposed to fHbF, the PBS exposed control vessels were completely normal in appearance, as verified by independent observers blinded to the groups. Light microscopy of flow-conditioned HPAECs from normal pregnancies showed that 0.3mg/mL fHbF reduced cell density and disrupted normal cell morphology, preventing cell alignment with flow compared to controls ( Figure 4D & C, respectively) .
fHbF activates the feto-placental endothelium: fHbF promoted HPAEC angiogenesis on Matrigel;
suggested by increased 'tubule' branching intensity (Supplementary Figure 3) . This was consistent with the findings from a 'cell stress' proteome array for fHbF-exposed HPAECs. Within this array, several proteins associated with enhanced angiogenesis (DKK-4), fatty acid uptake, lipid peroxidation, vascular remodeling (FABP-1), and inflammation (FABP-1 and NFkappa-B) were up-regulated (fHbF 0.3mg/mL; Table 2 ). These effects were confirmed in an investigation of endothelial nuclear translocation of NFκB and cytokine release. 
Discussion
We found fHbF is elevated in the fetal circulation of FGR pregnancy, commensurate with modifications to levels of biochemical markers acting as endogenous heme handling agents. Elevations in fHbF levels in FGR plasma are likely to be inconsequential of hemolysis, since fetal plasma LDH levels were not different between groups. Such elevated levels of fHbF caused vasoconstriction in the ex vivo human placenta dual perfusion model, by sequestering NO. This was confirmed biochemically using NO donation to oxy-fHbF using spectrophotometry and in a HPAEC cell-flow model, where liberated levels of NO were reduced when exposed to fHbF. Furthermore, pathophysiological levels of fHbF evoked endothelial inflammation in In validating increased fHbF levels in the FGR group as being a true in vivo event we measured the levels of other biochemical markers including some linked to cell free heme handling. The significant elevation in EPO levels in FGR is in keeping with placental hypoxia frequently observed in this disease; a process that may potentiate erythrogenesis. That said, our finding of no difference in LDH between groups indicates that a significant contribution of the fHbF plasma elevation in some FGR cases could arise through a mechanism of non-marrow hematopoeisis and independent of mechanical hemolysis. That embryonic tissue itself has an intrinsic capacity for α an γ globin production is a finding previously demonstrated in preeclampsia and other disciplines, and our data now supports this notion in FGR. (12, 42) Finding a reduction in fetal plasma hemopexin in FGR suggests that most of the circulating levels have been depleted through chaperoning fetal heme to the maternal liver. Fetal plasma hemopexin levels are normally lower than adult levels, consequential of a shorter half-life of fetal erythrocytes compared to adult erythrocytes and a greater need for heme detoxification of the fetal circulation (43) . A further reduction of hemopexin in FGR fetal plasma suggests an even higher in vivo heme load in this disease. An elevation in fetal plasma A1M could be indicative of an attempt to compensate for higher heme levels in FGR, in keeping with similar observations in the maternal circulation in preeclampsia, where fHbF is also elevated (44) .
fHbF evoked changes to blood flow resistance in the placenta: Within the ex vivo perfused human placenta, fHbF increased feto-placental blood flow resistance through an NO-dependent mechanism. The response was dose-dependent and confirmed through in vitro testing with an NO donor, with the most prominent effects observed at the pathophysiological levels of fHbF found in FGR cord plasma.
Nevertheless, poor recoverability from vasoconstriction also suggests a secondary (NO-independent) mechanism is at play. This non-recoverable vasoconstriction may be linked with the pronounced endothelial blebbing evoked by fHbF in chorionic plate vessels.
With loss of morphological conformity in flow-cultured HPAECs exposed to fHbF, alongside an 80% reduction in detectable NO, we propose that this atypical fHbF-evoked endothelial topography causes elevated feto-placental resistance and a decline in placental function. Increasing the length of the pathway in the placental transfer of hydrophilic nutrients is a separate consideration to any other additional dysregulation that might occur to the facilitated and active transport processes of nutrients across the syncytiotrophoblast. Here, we refer to the under-explored effects on the feto-placental endothelium. (45) Such dysregulated endothelial morphology is a feature of rhesus incompatibility of the new-born, another fHbF-laden vascular disease, associated with cytoplasmic blebs projecting from the endothelial cells of terminal villous capillaries with concomitant basement membrane thickening. (46) This small cohort study of FGR cases was diagnosed on solitary Delphi-consensus of birthweight centile cytokines occurs in fHbF exposed HPAECs. Both IL-1α and TNFα were significantly increased following fHbF exposure and NFκB nuclear translocation. To contextualize this, we suggest that a secondary NOindependent vasoconstriction observed in the perfused placenta might be explained by NFκB-dependent endothelial inflammation. Other notable directional responses in the cell stress array included a significant induction of the pro-angiogenic mediator DKK-4, an observation which paralleled increased tubule formation for fHbF-exposed HPAECs grown on Matrigel. There was also an increase in FABP-1 synthesis; a mediator of lipid handling, and a transcriptional regulator previously implicated in FGR. (49, 50) .
Hypothesised sequelae of events leading to poor pregnancy outcome: We propose a novel mechanism whereby unchecked fHbF within the human placenta, and potentially the fetus, establishes a vicious spiral of events beginning with NO sequestration. This significantly contributes to vasoconstriction and reduced vasodilatory paracrine signalling, promoting vaso-occlusion with localised erythrocyte extravasation. In the absence of adequate heme-handling capacity (HO-1), elevated fHbF levels provokes vascular inflammation, endothelial stress, proliferative placental angiogenesis and activation of a cytokine-dominated immune response. Figure 6 illustrates this potential route to feto-placental compromise. With prolonged or severe hematologic dysfunction, the protective defences of the fetus become fully ablated with wholesale vascular collapse and fetal demise. Indeed, work from our laboratory shows prominent avascularity as a feature of peripheral lobules in FGR pregnancy (51) . We therefore consider this mechanism a previously unrecognised pathway to FGR and potentially stillbirth. This knowledge will lead to future strategies to identify and treat failing pregnancies associated with incapacity to handle an elevated fetal heme load. 48 hours) and exposed to either PBS control (C) or 0.3mg/mL fHbF; scale bar = 50 μm (D). vasculoprotective defences and heme-scavenging systems including haptoglobin, hemopexin, albumin and α1 microglobulin [2] . Nitric oxide (NO) sequestration occurs [3] , causing increased vascular resistance [4] , reduced feto-placental blood flow [5] , placental microvascular congestion, and feto-placental hypertension [6] . Endothelial cells lose structural integrity [7] . Disturbed lipid handling may contribute to accelerated thrombosis and vascular occlusion [8] . As oxygen and nutrient delivery becomes compromised, fetal growth restriction (FGR) is a highly plausible clinical end point of vascular demise. Stillbirth may result when placental insufficiency passes an extreme threshold of diminished feto-placental perfusion [9] . 
